Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Colorectal Cancer ORLANDO, FLORIDA / ACCESS Newswire…
Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly…
Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly…
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP…
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire /…
Experienced medical executive advances to permanent role following successful leadership as Interim CMOSEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026…
HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal…
Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy aloneElraglusib…
-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential-…
– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and…